Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could 4 months of chemo be enough for stomach cancer?

NCT ID NCT03399110

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment works just as well to prevent cancer from coming back, while causing fewer side effects. Participants are adults aged 18-80 with stage II or III stomach cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,024 people

The number who actually took part.

Started

Jan 2018

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years. 2. Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction, staged as II, IIIA, or IIIB according to the American Joint Committee on Cancer classification system, eighth edition. 3. Underwent R0 gastrectomy with D2 lymphadenectomy. 4. No other concurrent malignancies. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. No contraindications to chemotherapy. Exclusion Criteria: 1. Receipt of preoperative treatment, including radiation therapy, chemotherapy, or immunotherapy. 2. Patients with stage I, IIIC, or IV gastric cancer. 3. Severe cardiac, pulmonary, neurologic, hepatic, or other major organ dysfunction. 4. Known or suspected drug allergies. 5. Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer

Contacts and locations

Locations

  • Changhai Hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Liaoning Cancer Hospital

    Shenyang, China

  • Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University

    Shanghai, China

  • Shanghai East Hospital

    Shanghai, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.